Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo
Section snippets
Materials and methods
Animals. Adult (6–8 weeks old) FVB transgenic mice, with the transgene comprising of the 15-kb HO-1 promoter driving expression of the reporter gene luciferase (luc), or HO-1-luc [35], were obtained from the Stanford Transgenic Animal Facility (Stanford, CA) and provided water and food ad libitum.
Reagents. Statins: simvastatin, lovastatin (EMD Biosciences, La Jolla CA), atorvastatin (Pfizer, New York, NY), and rosuvastatin (AstraZeneca, Wilmington DE) were dissolved in 30-μl Tween 80. The
HO activity
Fig. 1 and Table 1 show HO activity in the liver, brain, lung, and heart tissues 24 h after treatment with statins. After treatment with simvastatin, HO activity significantly increased 1.12-, 1.19-, and 1.70-fold in the liver, lung, and heart, respectively. No significant change in brain HO activity was observed following simvastatin treatment. Atorvastatin and rosuvastatin treatment resulted in similar significant increases in HO activity in the brain (1.06- and 1.16-fold), lung (1.11- and
Discussion
Pleiotropic mechanisms beyond the reduction of plasma cholesterol have been repeatedly shown to contribute to the anti-atherogenic and tissue-protective properties of statins. Based on previously published protocols and dosing regimens of statins administered to mice [42], [43], we first characterized the effects of four statins with varying structures and lipophilicities on in vivo HO activity. All four statins tested induced HO activity, but had varying tissue specificity profiles (Table 1).
Acknowledgments
This work was supported in part by National Institutes of Health Grant #HD58013, the Mary L. Johnson Research Fund, and the Christopher Hess Research Fund.
References (61)
- et al.
The evolving role of statins in the management of atherosclerosis
J. Am. Coll. Cardiol.
(2000) - et al.
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?
Lancet
(1996) - et al.
The lipid and non-lipid effects of statins
Pharmacol. Ther.
(2003) - et al.
Heme oxygenase-1: unleashing the protective properties of heme
Trends Immunol.
(2003) - et al.
Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels
Atherosclerosis
(2002) - et al.
Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis
J. Biol. Chem.
(2002) - et al.
Differential regulation of heme oxygenase isozymes by Sn- and Zn-protoporphyrins: possible relevance to suppression of hyperbilirubinemia
Biochim. Biophys. Acta
(1992) - et al.
Polymerized hemoglobin induces heme oxygenase-1 protein expression and inhibits intercellular adhesion molecule-1 protein expression in human lung microvascular endothelial cells
J. Am. Coll. Surg.
(2005) - et al.
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells
J. Hepatol.
(2003) - et al.
HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways
Cell Signal.
(2006)
Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1
Biochem. Biophys. Res. Commun.
The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells
Free Radic. Biol. Med.
Heme oxygenase activity as measured by carbon monoxide production
Anal. Biochem.
Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible
J. Biol. Chem.
Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice
Neurobiol. Aging
Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia
Atherosclerosis
Heme oxygenase 1 transgenic mice as a model to study neuroprotection
Methods Enzymol.
In situ hybridization and immunohistochemical localization of heme oxygenase-2 mRNA and protein in normal rat brain: differential distribution of isozyme 1 and 2
Mol. Cell. Neurosci.
Current perspectives on statins
Circulation
Anti-atherosclerotic effects of statins: lessons from prevention trials
J. Cardiovasc. Risk
Statins and risk of coronary heart disease
JAMA
Serum cholesterol in young men and subsequent cardiovascular disease
N. Engl. J. Med.
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors
Arterioscler. Thromb. Vasc. Biol.
Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway
Nat. Med.
Transfection of the human heme oxygenase gene into rabbit coronary microvessel endothelial cells: protective effect against heme and hemoglobin toxicity
Proc. Natl. Acad. Sci. USA
Heme oxygenase: a novel target for the modulation of the inflammatory response
Nat. Med.
Biliverdin reductase: a major physiologic cytoprotectant
Proc. Natl. Acad. Sci. USA
Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease
Arterioscler. Thromb. Vasc. Biol.
Association of serum bilirubin concentration with risk of coronary artery disease
Clin. Chem.
Heme oxygenase-1 protects against vascular constriction and proliferation
Nat. Med.
Cited by (92)
Effect of statins on abdominal aortic aneurysm
2022, European Journal of Pharmaceutical SciencesHeme oxygenase-1 affects cytochrome P450 function through the formation of heteromeric complexes: Interactions between CYP1A2 and heme oxygenase-1
2021, Journal of Biological ChemistryLovastatin protects against cisplatin-induced hearing loss in mice
2020, Hearing ResearchCitation Excerpt :The goal of the present study was to determine whether lovastatin could prevent cisplatin-induced hearing loss using a previously described and clinically relevant mouse model of cisplatin-induced ototoxicity (Fernandez et al., 2019). Lovastatin was selected as it is known to cross the blood-brain barrier (Hsu et al., 2006), a feature that may imply its ability to cross the blood-labyrinth barrier. The blood-labyrinth barrier remains a physiologic obstacle to many drugs designed to target the inner ear (Nyberg et al., 2019).